Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.

Guichard, S; Montazeri, A; Chatelut, E; Hennebelle, I; Bugat, R; Canal, P

Guichard, S; Montazeri, A; Chatelut, E; Hennebelle, I; Bugat, R; Canal, P.

Affiliation

Guichard S; Groupe de Pharmacologie clinique et expérimentale (EA 3035), Institut Claudius Regaud, rue de Pont St Pierre, 31052 Toulouse Cedex, France. guichard@icr.fnclcc.fr

Clin Cancer Res ; 7(10): 3222-8, 2001 Oct.

Article in En | MEDLINE | ID: mdl-11595718

Subject(s)

Antineoplastic Agents/therapeutic use; Ovarian Neoplasms/prevention & control; Topotecan/therapeutic use; Animals; Antineoplastic Agents/adverse effects; Antineoplastic Agents/pharmacokinetics; DNA Topoisomerases, Type I/metabolism; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms/enzymology; Ovarian Neoplasms/pathology; Time Factors; Topoisomerase I Inhibitors; Topotecan/adverse effects; Topotecan/pharmacokinetics; Treatment Outcome; Tumor Cells, Cultured; Weight Loss/drug effects; Xenograft Model Antitumor Assays

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Topotecan / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2001 Type: Article Affiliation country: France

Search on Google

XML

PubMed Links